Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Probiotic capsules show promise for constipation relief

NCT ID NCT06730594

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily probiotic capsule (Bio-K+) could help adults with functional constipation have more complete and comfortable bowel movements. Over 12 weeks, 168 participants took either the probiotic or a placebo. Researchers tracked changes in bowel movement frequency and stool consistency to see if the probiotic made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bio-K+ probiotic capsules (VL-BK-02)
What this could lead to
If successful, this probiotic could offer a natural, over-the-counter option to help people with chronic constipation have more regular and comfortable bowel movements.
What could go wrong
This is a small, completed trial with 168 participants. Probiotics affect people differently, and results may not apply to everyone. The placebo effect is also common in constipation studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

168 people

The number who actually took part.

Started

Jan 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals agreed to the signed and dated informed consent form. 2. Male and female individuals of age between 18 to 60 years (both values included) 3. Individuals who meet Rome IV diagnostic criteria for functional constipation as indicated by the criteria fulfilled for the last 3 months with symptoms onset at least 6 months prior to diagnosis: i. Must include two or more of the following criteria: 1. Fewer than three SBMs per week 2. Straining during more than ¼ (25%) of defecations 3. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations 4. Sensation of incomplete evacuation more than ¼ (25%) of defecations 5. Sensation of anorectal obstruction/ blockage more than ¼ (25%) of defecations 6. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor) ii. Loose stools are rarely present without the use of laxatives iii. Insufficient criteria for irritable bowel syndrome 4. Individuals willing to comply with all study procedures and availability for the duration of the study as per the protocol. 5. Individuals willing to maintain the same dietary and physical activity practices throughout the study period. 6. Individuals with fewer than three CSBMs per week. Exclusion Criteria: 1. Individuals with well-known, organic cause of constipation (Polyps, hemorrhoids, etc.) 2. Individuals with anorectal pathology 3. Individuals with history of gastrointestinal surgery including appendisectomy. 4. Individuals with any alarming symptoms (i.e. rectal bleeding, weight loss, jaundice) as judged by the Investigator. 5. Individuals with concurrent chronic GI pathology (e.g. IBD, cystic fibrosis, short gut, celiac disease, frequent diarrhea without laxative). 6. Current pharmacological treatment related to constipation (e.g. prosecretory agents, antidepressants, antispasmodics, enterokinetic) 7. Individuals consuming dietary treatment (e.g. synbiotics, herbal extracts, fibers) or taking other therapies for treating constipation (e.g. cognitive behavior therapy, acupuncture, biofeedback, complementary and alternative Medicine) within 1 month prior to screening. 8. Use of antibiotics within 1 month prior to screening. 9. Use of products containing probiotics, prebiotics, postbiotics, within 1 month prior to screening 10. Opioids-induced constipation. 11. Regular use of any drug or dietary supplement known to cause constipation (e.g. iron, opioids, sucralfate, misoprostol, 5-HT- antagonists, antacids with magnesium, calcium or aluminum, antidiarrheal medication, anticholinergic agents, calcium supplements, calcium channel blockers, tricyclic antidepressants or NSAIDs) within 1 month prior to screening. 12. Immuno-compromised participants. 13. Participants on immunosuppressive agents (e.g. heart or kidney transplant, chemotherapy agents, oral prednisolone) 14. History of cancer . 15. Individuals with known history of diabetes mellitus and are on medication for the same. 16. Individuals suffereing from Diabetic gastroparesis. 17. History of uncontrolled hypertension and/or systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. 18. Individuals with impaired thyroid function reported by TSH less than 0.4 mIU/L and more than 5 mIU/L will be excluded. However, individuals on a stable dose of medication for past 6 months and within the aforementioned range, can be considered. 19. Psychiatric or behavioral disorders as judged by the Investigator 20. Individuals with known food allergy. 21. Individuals with eating disorders (e.g., anorexia, bulimia) 22. Pregnancy or lactation 23. Known allergic reactions to any components of the probiotics or placebo. 24. Individuals participating in other interventional study within 90 days prior to screening. 25. Individuals with a history of alcohol or drug abuse based on medical history, physical examination, or the Investigators clinical judgment. 26. Current Smokers. 27. Individuals with more than 14 SBMs per week.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Functional constipation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AK Superspeciality Clinic

    Pune, Maharashtra, 411014, India

  • Anand Multispeciality Hospital

    Vadodara, Gujarat, 390016, India

  • Care Multispecialty Hospital

    Pune, Maharashtra, 412207, India

  • Gastrohub Hospital

    Pune, Maharashtra, 411027, India

  • Krishna Hospital

    Varanasi, Uttar Pradesh, 221005, India

  • Lifeline multispecialty Hospital

    Pune, Maharashtra, 412101, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.